Cardiovascular
How do AF comorbidity patterns change care and outcomes?
Open access · cc by · source: Europe PMC
In 32,560 AF patients, six comorbidity phenotypes ranged from low complexity to high complexity, with cardiometabolic/high-complexity groups facing higher event risk despite more anticoagulation.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Comorbidity patterns in atrial fibrillation relate to management and outcomes.
AF comorbidity patterning work shows how co-occurring diseases shape clinical impact beyond AF alone.
Evidence for the claim as stated.
Broad elderly inpatient multimorbidity spectrum vs AF-centered comorbidity patterns and impact
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
Broad elderly inpatient multimorbidity spectrum vs AF-centered comorbidity patterns and impact
Study at a glance
- Design
- Cohort — Prospective Global GLORIA-AF Registry comorbidity phenotype analysis
- N
- N=32560 · AF patients; mean age 70.0 ± 10.5 years; 45.4% female
- Population
- Adults with atrial fibrillation in a global prospective registry
- Outcome
- Comorbidity phenotypes linked to management and long-term prognosis
Structured fields used in claim comparison tables when every cited study has a complete layer.
Inspect source passages
How do AF comorbidity patterns change care and outcomes?
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
32,560 AF patients included.
Results 32,560 AF patients (mean age 70.0 ± 10.5 years, 45.4% females) were included.
Low complexity was 39.2% of patients.
We identified 6 phenotypes: (i) low complexity (39.2% of patients); (ii) cardiovascular (CV) risk factors (28.2%); (iii) atherosclerotic (10.2%); (iv) thromboembolic (8.1%); (v) cardiometabolic (7.6%) and (vi) high complexity (6.6%).
Key findings
Six phenotypes: low complexity (39.2%), CV risk factors (28.2%), atherosclerotic (10.2%), thromboembolic (8.1%), cardiometabolic (7.6%), high complexity (6.6%). More complex groups used more OACs; cardiometabolic and high-complexity groups had the highest primary-outcome HRs (~1.37 and ~1.47).
Methodology
Analyzed the Prospective Global GLORIA-AF Registry to cluster comorbidity phenotypes and relate them to oral anticoagulant/rate-control use and long-term primary outcomes.
Limitations
Registry observational associations cannot prove that changing phenotype classification improves outcomes; residual confounding and regional practice variation remain.
Related papers in this topic
Same topic cluster — not a recommendation engine.